Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction
- PMID: 758990
- DOI: 10.1161/01.cir.59.2.226
Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction
Abstract
The electrophysiologic effects of intravenously administered disopyramide (2 mg/kg) on three parameters of sinus node function were examined in 16 symptomatic patients with sinus node dysfunction. Based on their ECG data before study, patients were subdivided into group A (n = 8), those with sinus pauses and/or sinoatrial (SA) exit block; and group B (n = 8), those with sinus bradycardia. Disopyramide shortened spontaneous cycle length in 10 of 16 patients and lengthened it in six--markedly so (91%) in one patient. Estimated SA conduction time decreased in seven of 14 patients and increased in seven. Two patients developed second degree SA exit block after disopyramide. Maximum sinus node recovery time was prolonged by disopyramide in 11 of 16 patients and markedly so in four. For the group as a whole there was no significant difference in spontaneous cycle length, maximum sinus node recovery time or estimated SA conduction time. P-wave and QRS durations and H-V intervals were significantly lengthened by disopyramide. Marked depression of the three parameters of sinus node function occurred in three group A patients and in one group B patient who had persistent severe sinus bradycardia. These four patients also had secondary pauses after termination of rapid atrial pacing under control conditions. Disopyramide should be administered cautiously to patients with sinus node dysfunction, particularly those with sinus pauses, SA exit block or secondary pauses.
Similar articles
-
Disopyramide phosphate (Norpace): a new antiarrhythmic drug.Circulation. 1979 Feb;59(2):236-7. doi: 10.1161/01.cir.59.2.236. Circulation. 1979. PMID: 758991 No abstract available.
-
Electrophysiological effects of disopyramide phosphate in patients with sinus node dysfunction.Jpn Circ J. 1982 Jul;46(7):693-700. doi: 10.1253/jcj.46.693. Jpn Circ J. 1982. PMID: 6808188
-
[Efficacy and tolerance of disopyramide in arrhythmia associated with sinus node dysfunction].Arch Mal Coeur Vaiss. 1991 Jun;84(6):837-42. Arch Mal Coeur Vaiss. 1991. PMID: 1898218 Review. French.
-
Electrophysiological effects of disopyramide in patients with bundle branch block.Circulation. 1979 Feb;59(2):215-25. doi: 10.1161/01.cir.59.2.215. Circulation. 1979. PMID: 758989
-
Disopyramide.Ann Intern Med. 1982 Mar;96(3):337-43. doi: 10.7326/0003-4819-96-3-337. Ann Intern Med. 1982. PMID: 7036817 Review.
Cited by
-
New antiarrhythmic drugs: their place in therapy.Drugs. 1981 Nov;22(5):363-400. doi: 10.2165/00003495-198122050-00002. Drugs. 1981. PMID: 6800757 Review. No abstract available.
-
The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels.Front Pharmacol. 2022 May 2;13:809802. doi: 10.3389/fphar.2022.809802. eCollection 2022. Front Pharmacol. 2022. PMID: 35586063 Free PMC article.
-
Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.Drugs. 1987 Aug;34(2):151-87. doi: 10.2165/00003495-198734020-00001. Drugs. 1987. PMID: 3304965 Review.
-
Impaired neuronal sodium channels cause intranodal conduction failure and reentrant arrhythmias in human sinoatrial node.Nat Commun. 2020 Jan 24;11(1):512. doi: 10.1038/s41467-019-14039-8. Nat Commun. 2020. PMID: 31980605 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources